nach oben

Current HIV/AIDS Reports

Erschienen in:

28.01.2022 | The Global Epidemic (S Vermund, Section Editor)

HIV and SARS-CoV-2: Tracing a Path of Vaccine Research and Development

verfasst von: Brittany Ober Shepherd, David Chang, Sandhya Vasan, Julie Ake, Kayvon Modjarrad

Erschienen in: Current HIV/AIDS Reports | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review examines the major advances and obstacles in the field of HIV vaccine research as they pertain to informing the development of vaccines against SARS-CoV-2.

Recent Findings

Although the field of HIV research has yet to deliver a licensed vaccine, the technologies developed and knowledge gained in basic scientific disciplines, translational research, and community engagement have positively impacted the development of vaccines for other viruses, most notably and recently for SARS-CoV-2. These advances include the advent of viral vectors and mRNA as vaccine delivery platforms; the use of structural biology for immunogen design; an emergence of novel adjuvant formulations; a more sophisticated understanding of viral phylogenetics; improvements in the development and harmonization of accurate assays for vaccine immunogenicity; and maturation of the fields of bioethics and community engagement for clinical trials conducted in diverse populations.

Summary

Decades of foundational research and investments into HIV biology, though yet to yield an authorized or approved vaccine for HIV/AIDS, have now paid dividends in the rapid development of safe and effective SARS-CoV-2 vaccines. This latter success presents an opportunity for feedback on improved pathways for development of safe and efficacious vaccines against HIV and other pathogens.

Wolff JA, et al. Direct gene transfer into mouse muscle in vivo. Science. 1990;247(4949 Pt 1):1465–8.PubMedCrossRef

Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics–developing a new class of drugs. Nat Rev Drug Discov. 2014;13(10):759–80.PubMedCrossRef

Coughlan L, et al. Heterologous two-dose vaccination with Simian adenovirus and poxvirus vectors elicits long-lasting cellular immunity to influenza virus A in healthy adults. EBioMedicine. 2018;29:146–54.PubMedPubMedCentralCrossRef

Dicks MD, et al., A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS One, 2012. 7(7): e40385.

Barouch DH, et al. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13–19). Lancet. 2018;392(10143):232–43.PubMedPubMedCentralCrossRef

Sadoff J, et al., Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine. New England Journal of Medicine, 2021.

Folegatti PM, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet. 2020;396(10249):467–78.CrossRef

Clinicaltrials.gov. Safety and immunogenicity study of DNA.HTI, MVA.HTI and ChAdOx1.HTI in HIV-1-positive Patients (AELIX-002). [cited 2021 7Jun]; Available from: https://clinicaltrials.gov/ct2/show/NCT03204617.

Polack FP, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15.PubMedCrossRef

10.

Baden LR, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2020;384(5):403–16.PubMedCrossRef

11.

Gaschen B, et al. Diversity considerations in HIV-1 vaccine selection. Science. 2002;296(5577):2354–60.PubMedCrossRef

12.

Graham BS, Gilman MSA, McLellan JS. Structure-based vaccine antigen design. Annu Rev Med. 2019;70:91–104.PubMedPubMedCentralCrossRef

13.

Rappuoli R. Reverse vaccinology. Curr Opin Microbiol. 2000;3(5):445–50.PubMedCrossRef

14.

Kwong PD, What are the most powerful immunogen design vaccine strategies? A structural biologist's perspective. Cold Spring Harb Perspect Biol, 2017. 9(11).

15.

Ward AB, Wilson IA. Innovations in structure-based antigen design and immune monitoring for next generation vaccines. Curr Opin Immunol. 2020;65:50–6.PubMedPubMedCentralCrossRef

16.

Liu H, et al. The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects. Protein Cell. 2018;9(7):596–615.PubMedPubMedCentralCrossRef

17.

Lyumkis D, et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science. 2013;342(6165):1484–90.PubMedPubMedCentralCrossRef

18.

Julien JP, et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science. 2013;342(6165):1477–83.PubMedCrossRef

19.

Haynes BF, et al. Immune-correlates analysis of an hiv-1 vaccine efficacy trial. N Engl J Med. 2012;366(14):1275–86.PubMedPubMedCentralCrossRef

20.

Sanders RW, Moore JP. Native-like Env trimers as a platform for HIV-1 vaccine design. Immunol Rev. 2017;275(1):161–82.PubMedPubMedCentralCrossRef

21.

Sanders RW, et al., HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science, 2015. 349(6244): p. aac4223.

22.

Scheid JF, et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science. 2011;333(6049):1633–7.PubMedPubMedCentralCrossRef

23.

McLellan JS, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science. 2013;342(6158):592–8.PubMedPubMedCentralCrossRef

24.

McLellan JS, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science. 2013;340(6136):1113–7.PubMedPubMedCentralCrossRef

25.

Stewart-Jones GB, et al., A cysteine zipper stabilizes a pre-fusion f glycoprotein vaccine for respiratory syncytial virus. PLoS One, 2015. 10(6): e0128779.

26.

Joyce MG, et al. Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV. Nat Struct Mol Biol. 2016;23(9):811–20.PubMedPubMedCentralCrossRef

27.

Krarup A, et al. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat Commun. 2015;6:8143.PubMedCrossRef

28.

Wrapp D, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–3.PubMedPubMedCentralCrossRef

29.

Pitisuttithum P, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok Thailand. J Infect Dis. 2006;194(12):1661–71.PubMedCrossRef

30.

Rerks-Ngarm S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361(23):2209–20.PubMedCrossRef

31.

O’Connell RJ, et al. Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene. J Infect Dis. 2016;213(12):1946–54.PubMedPubMedCentralCrossRef

32.

Weissburg RP, et al. Characterization of the MN gp120 HIV-1 vaccine: antigen binding to alum. Pharm Res. 1995;12(10):1439–46.PubMedCrossRef

33.

Flynn NM, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005;191(5):654–65.PubMedCrossRef

34.

Pegu P, et al. Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial. J Virol. 2013;87(3):1708–19.PubMedPubMedCentralCrossRef

35.

Tuero I, et al., Mucosal B cells are associated with delayed SIV acquisition in vaccinated female but not male rhesus macaques following SIVmac251 rectal challenge. PLoS Pathog, 2015. 11(8): e1005101.

36.

Fouts TR, et al. Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection. Proc Natl Acad Sci U S A. 2015;112(9):E992–9.PubMedPubMedCentralCrossRef

37.

Iyer SS, et al. Codelivery of envelope protein in alum with MVA vaccine induces CXCR3-Biased CXCR5+ and CXCR5- CD4 T Cell Responses in Rhesus Macaques. J Immunol. 2015;195(3):994–1005.PubMedCrossRef

38.

Barouch DH, et al. Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. Science. 2015;349(6245):320–4.PubMedPubMedCentralCrossRef

39.

Apostólico Jde S, et al., HIV envelope trimer specific immune response is influenced by different adjuvant formulations and heterologous prime-boost. PLoS One, 2016. 11(1): e0145637.

40.

Leroux-Roels I, et al. Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems. Vaccine. 2010;28(43):7016–24.PubMedCrossRef

41.

Alving CR, et al. Liposomal adjuvants for human vaccines. Expert Opin Drug Deliv. 2016;13(6):807–16.PubMedCrossRef

42.

Beck Z, Matyas GR, Alving CR. Detection of liposomal cholesterol and monophosphoryl lipid A by QS-21 saponin and Limulus polyphemus amebocyte lysate. Biochim Biophys Acta. 2015;1848(3):775–80.PubMedCrossRef

43.

Beck Z, et al. Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21. Vaccine. 2015;33(42):5578–87.PubMedCrossRef

44.

Wieczorek L, et al. Comparable antigenicity and immunogenicity of oligomeric forms of a novel, acute HIV-1 subtype C gp145 envelope for use in preclinical and clinical vaccine research. J Virol. 2015;89(15):7478–93.PubMedPubMedCentralCrossRef

45.

Clinicaltrials.gov. HIV Vaccine in HIV-uninfected Adults. [cited 2021 7Jun]; Available from: https://clinicaltrials.gov/ct2/show/NCT04658667.

46.

Robb ML, et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis. 2012;12(7):531–7.PubMedPubMedCentralCrossRef

47.

Zolla-Pazner S, et al., Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLoS One, 2013. 8(1): p. e53629.

48.

Rerks-Ngarm S, et al. Randomized, double-blind evaluation of late boost strategies for HIV-Uninfected vaccine recipients in the RV144 HIV vaccine efficacy trial. J Infect Dis. 2017;215(8):1255–63.PubMedPubMedCentralCrossRef

49.

Easterhoff D, et al., Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. PLoS Pathog, 2017. 13(2): p. e1006182.

50.

Easterhoff D, et al. Boosting with AIDSVAX B/E enhances Env constant region 1 and 2 antibody-dependent cellular cytotoxicity breadth and potency. J Virol, 2020. 94(4).

51.

Easterhoff D, et al. HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions. JCI Insight, 2020. 5(2).

52.

Atmar RL, et al. Heterologous SARS-CoV-2 booster vaccinations - preliminary report. medRxiv, 2021.

53.

Montefiori D, et al. Antibody-based HIV-1 vaccines: recent developments and future directions. PLoS Med, 2007. 4(12): e348.

54.

Polonis VR, et al. Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology. 2008;375(2):315–20.PubMedCrossRef

55.

Joyce MG, et al. Efficacy of a broadly neutralizing SARS-CoV-2 ferritin nanoparticle vaccine in nonhuman primates. bioRxiv, 2021: p. 2021.03.24.436523.

56.

Weissman D, et al. D614G spike mutation increases SARS CoV-2 susceptibility to neutralization. Cell Host Microbe. 2021;29(1):23-31.e4.PubMedCrossRef

57.

Sholukh AM, et al. Evaluation of SARS-CoV-2 neutralization assays for antibody monitoring in natural infection and vaccine trials. medRxiv, 2020.

58.

Alter G, Barouch D. Immune correlate-guided hiv vaccine design. Cell Host Microbe. 2018;24(1):25–33.PubMedPubMedCentralCrossRef

59.

Gilbert PB, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science, 2021: p. eab3435.

60.

Khoury DS, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–11.PubMedCrossRef

61.

Dearlove B, et al. A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants. Proc Natl Acad Sci U S A. 2020;117(38):23652–62.PubMedPubMedCentralCrossRef

62.

Wu K, et al. Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice. bioRxiv, 2021: p. 2021.04.13.439482.

63.

CDC. Risk for COVID-19 Infection, hospitalization and death by race/ethnicity. 2021 23 Apr 2021 [cited 2021 10 May 2021]; Available from: https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-race-ethnicity.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fcommunity%2Fhealth-equity%2Fracial-ethnic-disparities%2Finfographic-cases-hospitalization-death.html.

64.

Williamson EJ, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430–6.PubMedPubMedCentralCrossRef

65.

Webb Hooper M, Nápoles AM, Pérez-Stable EJ, COVID-19 and racial/ethnic disparities. JAMA, 2020. 323(24): p. 2466–2467.

66.

Weintraub RL, et al. COVID-19 vaccine to vaccination: why leaders must invest in delivery strategies now. Health Aff (Millwood). 2021;40(1):33–41.CrossRef

67.

Katz IT, et al. From vaccine nationalism to vaccine equity - finding a path forward. N Engl J Med. 2021;384(14):1281–3.PubMedCrossRef

68.

AVAC. Applying global health advocacy to the COVID-19 response. [cited 2021 7Jun]; Available from: https://www.avac.org/covid.

69.

Killen J, Harrington M, Fauci AS. MSM, AIDS research activism, and HAART. Lancet. 2012;380(9839):314–6.PubMedCrossRef

70.

CoVPN. COVID-19 Prevention Network About Us. 2021 11 May 2021]; Available from: https://www.coronaviruspreventionnetwork.org/about-covpn/.

71.

CEAL. Community Engagement Alliance at a Glance. 11 May 2021]; Available from: https://covid19community.nih.gov/about.

72.

Yamey G, et al. Ensuring global access to COVID-19 vaccines. Lancet. 2020;395(10234):1405–6.PubMedPubMedCentralCrossRef

73.

NYTimes. The World is desperate for more COVID vaccines. Available from: https://www.nytimes.com/2021/01/12/opinion/world-covid-vaccines.html.

Titel: HIV and SARS-CoV-2: Tracing a Path of Vaccine Research and Development
verfasst von: Brittany Ober Shepherd
David Chang
Sandhya Vasan
Julie Ake
Kayvon Modjarrad
Publikationsdatum: 28.01.2022
Verlag: Springer US
Erschienen in: Current HIV/AIDS Reports / Ausgabe 1/2022
Print ISSN: 1548-3568
Elektronische ISSN: 1548-3576
DOI: https://doi.org/10.1007/s11904-021-00597-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2022

The Reproductive Transition: Effects on Viral Replication, Immune Activation, and Metabolism in Women with HIV infection

Social and Behavioral Impacts of COVID-19 on People Living with HIV: Review of the First Year of Research

Central Nervous System Impact of Perinatally Acquired HIV in Adolescents and Adults: an Update

Adventures in COVID-19 Policy Modeling: Education Edition

PEPFAR’s Role in Protecting and Leveraging HIV Services in the COVID-19 Response in Africa